Table 1 Clinicopathological features of eight NGS NRG1 fusion positive cases
From: Fluorescent in situ hybridization has limitations in screening NRG1 gene rearrangements
No. | Tumor type | Histological type | Gender | Age | Stage(T,N,M) | NRG1 fusion mode |
|---|---|---|---|---|---|---|
S201922867-3 | colorectal cancer | Adenocarcinoma | Male | 78 | II(T3,N0,M0) | NSD3:EXON3-NRG1:EXON 2 |
S201906567-2 | colorectal cancer | Adenocarcinoma | Female | 56 | II(T2,N0,M0) | WASR2:EXON2-NRG1:EXON6 |
S202022206 | Intrahepatic cholangiocarcinoma | Adenocarcinoma | Female | 39 | I(T1,N0,M0) | ATP1B1:EXON2-NRG1: EXON2 |
201766478 | Breast cancer | Invasive adenocarcinoma | Female | 51 | III(T2,N2,M0) | PLEKHA2:EXON4-NRG1: EXON6 |
201770699-3 | Lung cancer | NSCLC | Female | 46 | IV(T2,N0,M1) | NOTCH2:EXON1-NTR1:EXON12 |
F201900641-4 | Lung cancer | NSCLC | Female | 65 | II(T1,N2,M0) | TBC1019:EXON4-NRG1:EXON3 |
JF201900557 | Lung cancer | Mucinous adenocarcinoma | Female | 67 | I(T1,N0,M0) | CD74:EXON6-NRG1:EXON 6 |
JF202001074 | Lung cancer | Mucinous adenocarcinoma | Female | 70 | I(T1,N0,M0) | SDC4:EXON2-NRG1:EXON 6 |